Perrella Carmine, Carrus Dario, Costa Emilia, Schifano Fabrizio
I Clinica Psichiatrica, Policlinico Umberto I, Università La Sapienza di Roma, Viale Dell'Università, 30 - 00185, Rome, Italy.
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):158-63. doi: 10.1016/j.pnpbp.2006.08.012. Epub 2006 Oct 11.
Only a few studies have commented on the use of atypical antipsychotics for the treatment of Borderline Personality Disorder (BPD) features, including affective dysregulation and aggression. We aimed at evaluating both efficacy and safety of quetiapine in a sample of consecutive BPD patients.
29 BPD outpatients entered, and 23 completed, a 12 week, open-label, regime of quetiapine at an average daily dosage of 540 mg (range: 400-800 mg). Efficacy assessment psychometric instruments included: Hamilton Rating Scales for Depression (HAM-D); Brief Psychiatric Rating Scale (BPRS); Global Assessment of Functioning (GAF); Clinical Global Impression Scale (CGI); and Aggression Questionnaire (AQ).
Both completer and intent-to-treat analysis showed that most psychometric scales' scores exhibited a highly significant (HAM-D: p=.003; BPRS Hostility and Suspiciousness subscales; CGI; GAF; AQ: all at p=.000) improvement over time. Six patients dropped out early from treatment due to side effects; quetiapine was associated with two cases of transient thrombocytopenia.
Present findings would suggest that quetiapine may be effective for the treatment of a number of BPD features, including low mood and aggression. However, monitoring blood counts in patients receiving quetiapine seems to be justified.
仅有少数研究对非典型抗精神病药物用于治疗边缘型人格障碍（BPD）特征（包括情感失调和攻击性）进行过评论。我们旨在评估喹硫平对连续的BPD患者样本的疗效和安全性。
29名BPD门诊患者进入并完成了一个为期12周的喹硫平开放标签治疗方案，平均每日剂量为540毫克（范围：400 - 800毫克）。疗效评估心理测量工具包括：汉密尔顿抑郁量表（HAM - D）；简明精神病评定量表（BPRS）；功能总体评定量表（GAF）；临床总体印象量表（CGI）；以及攻击性问卷（AQ）。
完成者分析和意向性分析均显示，大多数心理测量量表的分数随时间呈现出高度显著的改善（HAM - D：p = .003；BPRS敌意和猜疑分量表；CGI；GAF；AQ：均为p = .000）。6名患者因副作用提前退出治疗；喹硫平与2例短暂性血小板减少症相关。
目前的研究结果表明，喹硫平可能对治疗多种BPD特征有效，包括情绪低落和攻击性。然而，对接受喹硫平治疗的患者监测血细胞计数似乎是合理的。
